BRILINTA PACKAGE INSERT PDF

BRILINTA® (ticagrelor) tablets can lower your chance of another heart attack or stroke. Learn more about saving on BRILINTA, talking to your doctor, and. Patient Information Leaflet. Package leaflet: Information for the user. Brilique 90 mg film-coated tablets ticagrelor. Read all of this leaflet carefully before you start . 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed.

Author: Daijinn Felrajas
Country: Chile
Language: English (Spanish)
Genre: Photos
Published (Last): 2 May 2004
Pages: 224
PDF File Size: 17.78 Mb
ePub File Size: 13.71 Mb
ISBN: 599-8-55182-926-6
Downloads: 33995
Price: Free* [*Free Regsitration Required]
Uploader: Gogul

Concomitant use is expected to increase ticagrelor exposure, which may increase bleeding risk. BRILINTA is used with aspirin to lower your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. Theoretically, the risk of bleeding may be increased, but some studies that combined these agents did not produce clinically significant bleeding events. Severe Coadministration of defibrotide with antithrombotic brilinfa like platelet inhibitors is contraindicated.

Major Consider the use of a parenteral anti-platelet agent for patients with acute coronary syndrome who require concomitant hydromorphone.

Evolving Treatment Paradigm in ACS | BRILINTA® (ticagrelor) tablets

Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Moderate Desirudin should be used with caution in conjunction with drugs packaye affect platelet function, due to the potential for an additive risk of bleeding. Major Avoid coadministration of ceritinib with ticagrelor due to increased ticagrelor exposure.

Moderate An additive risk of bleeding may be seen in patients receiving other platelet inhibitors in combination with danaparoid. Major Avoid concurrent administration of platelet inhibitors with rivaroxaban unless the benefit outweighs the risk of increased bleeding. Moderate An additive risk of bleeding may occur when platelet inhibitors are used with agents that cause clinically significant thrombocytopenia including antineoplastic agents, brilintq as chlorambucil.

Additionally, concomitant use of dihydrocodeine with ticagrelor may increase dihydrocodeine plasma concentrations, resulting in greater metabolism by CYP2D6, increased dihydromorphine concentrations, and prolonged opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.

Minor Coadministration of ticagrelor and telaprevir may result in increased exposure to ticagrelor which may ihsert the bleeding risk. Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention PCICABG, or other surgical procedures in the setting of ticagrelor.

Studies have shown that drugs that inhibit CYP3A4 can increase avanafil exposure.

Server Error

Moderate Monitor for loss of efficacy of ticagrelor during coadministration of ivosidenib; a ticagrelor dose adjustment may be necessary. Concomitant use may result in elevated plasma concentrations of dronabinol.

Moderate Avoid aspirin maintenance doses of more than mg with concomitant ticagrelor.

Ticagrelor is classified as FDA pregnancy risk category C. Although this interaction has not been studied by the manufacturer, and published literature suggests the potential for interactions to be low, taking these drugs together may increase the systemic exposure of terbinafine.

Moderate Use caution if coadministration of dronabinol with ticagrelor is necessary, and monitor for an increase in dronabinol-related adverse reactions e. Moderate Although anagrelide inhibits platelet aggregation at high doses, there is a potential additive risk for bleeding if anagrelide is given in combination with other agents that effect hemostasis such as ADP receptor antagonists including clopidogrel, prasugrel, ticagrelor, or ticlopidine.

Moderate Dual inhibitors of P-glycoprotein P-gp and CYP3A4, such as ticagrelor, are expected to increase the exposure and clinical effect of nintedanib. Minor Coadministration of ticagrelor indert boceprevir may result in increased exposure to ticagrelor which may increase the bleeding risk.

Moderate Prasterone is contraindicated for use in patients with active deep vein thrombosis, pulmonary embolism or history of these conditions. The benefit for patients who undergo primary percutaneous inaert intervention is unknown. Long-term coadminstration is not recommended. Plavix should be administered in conjunction with aspirin. During one in vitro study, coadministration with cyclosporine, a potent P-gp inhibitor, resulted in an fold and fold increase in the mean Cmax and AUC of rifaximin, respectively.

Moderate Increased effects from concomitant anticoagulant drugs including increased bruising or blood in the stool have been reported in patients taking methylsulfonylmethane, MSM. Ticagrelor is excreted into the milk of lactating rats.

Share With a Friend

In patients treated with PCI, it also reduces the rate of stent thrombosis. Moderate Monitor for decreased efficacy of ticagrelor brilinya coadministration with brigatinib is necessary.

Consider additional monitoring when concomitant use is medically necessary. Ticagrelor can cause ventricular pauses. Moderate Patients should be instructed to monitor for signs and symptoms of bleeding while taking vilazodone concurrently with salicylates or other platelet inhibitors and to promptly report any bleeding events to the practitioner.